Stocks of Resmed Inc (NYSE:RMD) traded higher last session on Wall Street, up 0.42% to $256.96.
RMD stock price is now 3.96% away from the 50-day moving average and 7.82% away from the 200-day moving average. The market capitalization of the company currently stands at $37.68B.
With the price target of $280, Morgan Stanley recently initiated with Overweight rating for Resmed Inc (NYSE: RMD). , while ‘Goldman’ rates the stock as ‘Buy’
In other news, FARRELL PETER C, Director sold 945 shares of the company’s stock on Jul 02 ’25. The stock was sold for $241,438 at an average price of $255.49. Upon completion of the transaction, the Director now directly owns 68,273 shares in the company, valued at $17.54 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 01 ’25, Chief Financial Officer Sandercock Brett sold 3,883 shares of the business’s stock. A total of $997,892 was realized by selling the stock at an average price of $256.99. This leaves the insider owning 84,283 shares of the company worth $21.66 million. A total of 0.70% of the company’s stock is owned by insiders.
During the past 12 months, Resmed Inc has had a low of $188.06 and a high of $263.05. As of last week, the company has a debt-to-equity ratio of 0.15, a current ratio of 3.41, and a quick ratio of 2.49. According to the stock market information, the enterprise value for the company is $37724798976, which is based on a 28.85 price-to-earnings ratio, a 1.97 price-to-earnings-growth ratio, and a beta of 0.77. The fifty day moving average price for RMD is $247.1686 and a two-hundred day moving average price translates $238.32065 for the stock.
The latest earnings results from Resmed Inc (NYSE: RMD) was released for 2025-03-31. The net profit margin was 26.15% and return on equity was 25.81% for RMD. The company reported revenue of $1.29 billion for the quarter, compared to $1.2 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.92 percent.
